We recommend upgrading to the latest Microsoft Edge, Google Chrome, or Firefox.
Dr. Tanya Murphy
Title: Av1ation: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 with Autism Spectrum Disorder (ASD)
Purpose/Description: To evaluate the efficacy, safety, and tolerability of an experimental drug RO5285119 compared to placebo. RO5285119 is a highly selective human V1a receptor antagonist that is shown to modulate social behaviors and is intended to improve social communication and interaction skills.
Type:
Medication/Clinical Trial
Participants:
Individuals aged 5-17 with high functioning ASD
Contact:
Kalie Pham via email at kaliepham@health.usf.edu
or by phone at (727) 767-8393.
Title: T-Force Gold: A Randomized, Double-blind, Placebo-controlled,
Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of
NBI-98854 for the Treatment of Pediatric Subjects with Tourette Syndrome
Purpose: To evaluate the efficacy, safety, and
tolerability of an experimental drug NBI-98854 (valbenazine tosylate) compared
to placebo in children ages 6-17 with Tourette syndrome. NBI-98854 is a
selective VMAT2 inhibitor under development for the treatment of TS after being
approved by the US Food and Drug Administration (FDA) for treatment of adults
with tardive dyskinesia (TD).
Type:
Medication/Clinical Trial
Participants:
Individuals aged 6-17 years with a diagnosis of
Tourette Syndrome
Contact:
Kalie Pham via email at kaliepham@health.usf.edu
or by phone at (727) 767-8393.
Title: Shine: A Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-dose Safety and Efficacy Study of SPD489 Compared with Placebo in Preschool Children Aged 4-5 Years with Attention-deficit/Hyperactivity disorder (ADHD)
Purpose/Description: To evaluate the efficacy of an experimental drug SPD489 (Lisdexamfetamine dimesylate) compared to placebo in preschool children (4-5 years of age) with Attention-deficit/Hyperactivity Disorder (ADHD).
Type:
Medication/Clinical Trial
Participants:
Individuals aged 4-5 years with primary diagnosis of ADHD (any subtype)
Contact:
Kalie Pham via email at kaliepham@health.usf.edu
or by phone at (727) 767-8393.
Title: Tic Treatment Preference: An Examination of Treatment Preference in Pediatric Tourette and Tic Disorder Population
Purpose/Description: To examine parent treatment preferences and factors associated with parent treatment preference for children with TS, other chronic tic disorders, and provisional tic disorder using an in-clinic survey administered to parents that are receiving treatment for their child at the Rothman Center.
Type:
Non-treatment/ Survey
Participants:
Individuals aged 7-17 with motor or phonic tics attending a scheduled appointment t at the Rothman Center
Contact:
Kalie Pham via email at kaliepham@health.usf.edu
or by phone at (727) 767-8393.
Title: Immune Characterization: Immune Factors and Psychosocial Correlates in Pediatric Tic Disorders and Obsessive Compulsive Disorder
Purpose/Description: To understand more about immune-related factors that might influence symptoms of tics, anxiety, and OCD in children. In particular, we are interested in how infections and other immune factors might contribute to increased symptoms in youth with tics, anxiety, or OCD. Also enrolling healthy controls.
Type:
Non-treatment
Participants:
Individuals aged 4-17 years attending a scheduled appointment at the Rothman Center
*Healthy
controls:
Individuals aged 4-17 years with no prior
diagnosis of any neuropsychiatric or developmental disorder and not receiving
special education services
Contact:Kalie Pham via email at kaliepham@health.usf.edu
or by phone at (727) 767-8393.
Title: A Brief Behavioral Treatment for Anxiety in Young Children
Purpose: To examine the effectiveness of a parent-led behavioral treatment for children ages 3 to 7 years old with problematic anxiety. Parents and youth receive individualized psychotherapy aimed to teach parents and children to effectively manage anxiety using evidence-based tools.
Title: Investigating the feasibility, acceptability, and initial efficacy of a comprehensive transdiagnostic treatment for complex comorbidity in Tourette Disorder.
Purpose: To develop and test a psychotherapeutic treatment for youth with Tourette Syndrome and co-occuring problems such as anxiety, depression, ADHD, and behavioral problems in youth ages 8-17. Youth receive individual psychotherapy personally tailored to address these problems.
Title: Treatment of Anxiety in Late Adolescents with Autism
Purpose: To develop and test a psychotherapeutic treatment for clinical anxiety that is personalized to the unique clinical characteristics of late adolescents (ages 16-21) with Autism Spectrum Disorders.
For all studies, contact: Dr. Jane Mutch, co-investigator with Dr. Adam Lewin by phone at (727) 767-8230.